Studies have been conducted in datasets of solid tumors, particularly those of melanoma and NSCLC types, which identified a reasonable correlation between PD-L1 expression on immunohistochemistry and response to PD-1/PD-L1 antagonistic agents (159). Here, PDCD1 is linked to melanoma.